Phathom Pharmaceuticals, Inc. (PHAT) Q2 FY26 Earnings Call

Profitability arrived early, but payer-workflow friction tempered 2026 revenue expectations. [3][4]

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-07-30
Length59 minutes
EPS$-0.08
EPS consensus$-0.15
Revenue$74.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All PHAT earnings ยท Back to PHAT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.